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Abstract 
Background 
The Aston Medication Adherence Study was designed to examine non-adherence to prescribed 
medicines within an inner-city population using general practice (GP) prescribing data. 
Objective 
To examine non-adherence patterns to prescribed oral medications within three chronic disease 
states and to compare differences in adherence levels between various patient groups to assist the 
routine identification of low adherence amongst patients within the Heart of Birmingham teaching 
Primary Care Trust (HoBtPCT). 
Setting 
Patients within the area covered by HoBtPCT (England) prescribed medication for dyslipidaemia, 
type-2 diabetes and hypothyroidism, between 2000 and 2010 inclusively. HoBtPCT’s population was 
disproportionately young, with seventy per cent of residents from Black and Minority Ethnic groups. 
Method 
Systematic computational analysis of all medication issue data from 76 GP surgeries dichotomised 
patients into two groups (adherent and non-adherent) for each pharmacotherapeutic agent within 
the treatment groups. Dichotomised groupings were further analysed by recorded patient 
demographics to identify predictors of lower adherence levels. Results were compared to an analysis 
of a self-report measure of adherence (using the Modified Morisky Scale© (MMAS-8)) and clinical 
value data (cholesterol values) from GP surgery records. 
Main outcome 
Adherence levels for different patient demographics, for patients within specific long-term 
treatment groups. 
Results 
Analysis within all three groups showed that for patients with the following characteristics, 
adherence levels were statistically lower than for others; patients: younger than 60 years of age; 
whose religion is coded as “Islam”; whose ethnicity is coded as one of the Asian groupings or as 
“Caribbean”, “Other Black” and “African”; whose primary language is coded as “Urdu” or “Bengali”; 
and whose postcodes indicate that they live within the most socioeconomically deprived areas of 
The Aston Medication Adherence Study – mapping the adherence patterns of an inner-city population 
2 
 
HoBtPCT. Statistically significant correlations between adherence status and results from the self-
report measure of adherence and of clinical value data analysis were found. 
Conclusion 
Using data from GP prescribing systems, a computerised tool to calculate individual adherence levels 
for oral pharmacotherapy for the treatment of diabetes, dyslipidaemia and hypothyroidism has been 
developed. The tool has been used to establish non-adherence levels within the three treatment 
groups and the demographic characteristics indicative of lower adherence levels, which in turn will 
enable the targeting of interventional support within HoBtPCT. 
350 Words 
Impact of findings on practice 
• The adherence status of patients taking oral pharmacotherapy for dyslipidaemia, type-2 
diabetes and hypothyroidism can be predicted by analysis of medication issue data from 
general practice (GP) surgeries. 
• It is possible to identify specific patient demographic factors indicative of lower adherence 
levels by analysis of recorded demographic data from GP prescribing systems. 
• By using information on adherence status and indicative patient demographic groupings, 
targeted support can be provided to patients to help address barriers to medication 
adherence. 
• Where adherence problems are suspected, a validated self-report adherence questionnaire 
(the Modified Morisky Scale© (MMAS-8)) could be used within healthcare locations (general 
practice surgeries, community pharmacies, etc.) to assist in the identification of low 
adherence levels in patients taking oral pharmacotherapy for dyslipidaemia, type-2 diabetes 
and hypothyroidism. 
Keywords 
Diabetes, Dyslipidaemia, Hypothyroidism, Medication adherence, Modified Morisky Scale, United 
Kingdom. 
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Introduction 
Adherence is “the extent to which the patient’s behaviour matches agreed recommendations from 
the prescriber”.1 While the accurate measurement of adherence may be complex, in developed 
nations it is estimated that 30-50% of all prescription medicines for long-term conditions are not 
taken as prescribed.2 As the scale of non-adherence to prescribed medicines, and the personal, 
social and financial costs resulting from this non-adherence have become more apparent, healthcare 
organisations have placed an increasing focus on obtaining rigorous data to inform both 
commissioning decisions and the development of suitable policies designed to ameliorate the impact 
of non-adherence. 
A number of approaches to measuring adherence have been adopted. Subjective (or ‘indirect’) 
strategies for measuring medication adherence focus largely on patient self-reporting. However, 
interpreting such reports is often problematic. Cramer and Mattson3 reported that patients who 
‘admit’ to not following recommendations tend to describe their behaviour accurately, whereas, 
patients who deny a failure to follow treatment advice have a tendency to report their behaviour 
inaccurately.4 Both ‘adherence diaries’ kept by patients and visual analogue scales of adherence 
overestimate adherence when compared to adherence measured objectively by electronic 
monitoring devices.5-6 Other indirect measures include pill counts and clinician assessments but 
these have been found to overestimate adherence and are impractical for large populations.7-8 
Objective (or ‘direct’) strategies usually involve the measurement of a chemical (i.e. a marker or 
metabolite) in a bodily fluid (i.e. blood or urine). However, such measurements are not available for 
all medications, are expensive and are also impractical in large populations.9 
Healthcare databases can be used to check when, for example, prescriptions are initially filled, 
refilled over the duration of treatment or are prematurely discontinued. Limitations associated with 
the use of such databases include an inability to determine if the patient actually consumed the 
prescribed medicine (i.e. obtaining the medicine does not ensure its use) and the potential for 
incomplete data sets (data may not be routinely captured and patients are free to use more than 
one pharmacy). However, the efficiency of using such databases for studies of adherence in large 
populations is highly advantageous where data is deemed to be complete and GP prescribing data 
appears to be predictive of subsequent pharmacy-based dispensing data with 93% of prescriptions 
issued by GPs being dispensed within seven days.7, 10 
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A combination of methods is often used in the study of adherence. Farley et al examined adherence 
rates as measured by an electronic monitoring device (Medication Event Monitoring System – 
MEMS) and pharmacy refill rates alongside measurement of viral load in HIV-infected children.11 
Both MEMS and pharmacy refill adherence rates were associated with virologic response (with 
MEMS providing the more robust measure). 
No single method of measuring adherence has been deemed optimal although in a 2008 Cochrane 
Review, Haynes et al stated “although objective measures are more expensive, they provide a more 
accurate measure of true adherence and should be incorporated into studies whenever possible”.12 
Furthermore, the WHO advocate a multi-method approach as the state-of the-art measurement of 
adherence behaviour.13 
The accurate measurement of adherence can be problematic, particularly amongst large 
populations. It was against this background that the healthcare organisation responsible for primary 
care services (at the time of the study) for approximately 300,000 people within the centre of 
Birmingham, UK (the Heart of Birmingham teaching Primary Care Trust; HoBtPCT), commissioned a 
study to establish the extent of non-adherence to medication within their geographical area of 
responsibility (since 31st March 2013, National Health Service restructuring has seen the abolition of 
Primary Care Trusts). HoBtPCT proposed to utilise the findings from the study to influence the design 
of newly commissioned healthcare interventions to maximise the impact any intervention can have 
on overall medication adherence levels. 
HoBtPCT’s population was disproportionately young; almost a third of the resident population was 
under 19 years of age.14 Seventy per cent of people in HoBtPCT were from Black and Minority Ethnic 
(BME) groups; the highest proportion of people from BME groups of any PCT in England.15 According 
to the Indices of Multiple Deprivation 2010 (IMD 2010), HoBtPCT was the most socioeconomically 
deprived PCT in England with two thirds of the population living in neighbourhoods that are in the 
most deprived quintile of neighbourhoods in England.14 Unemployment rates, particularly for men, 
were high. Religious belief played an important part in the lives of a large number of HoBtPCT 
residents and there were differences in the religious make-up of the population when compared to 
national (England) statistics. For example, according to 2001 Census data, 41% of HoBtPCT residents 
identified themselves as Christian (nationally, 72%), 29% identified themselves as Muslim (nationally, 
3%), 7% as Sikh (nationally, 0.7%) and 4% as Hindu (nationally, 1.1%) (the remaining groups being 
either Buddhist, Jewish, “other” religions or where religion was not stated).16 Therefore, it was 
imperative that HoBtPCT based any commissioning decisions on data relevant to its specific 
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population, rather than relying on published studies undertaken within demographically-different 
populations. 
Migration has been a feature of Birmingham life for generations and it continued to be a prominent 
aspect of life within HoBtPCT making language a major barrier to accessing services.15 A ‘language 
barrier’ did not present exclusively among ‘recent’ arrivals to HoBtPCT however. One fifth of adults 
within the parliamentary constituencies in the HoBtPCT area could only read and write English to 
pre-GCSE level (General Certificate of Secondary Education (GCSE) examinations are taken by 
students aged 14-16 in secondary education in England, Wales and Northern Ireland) and 
approximately 64% of dependent children aged 0-15 were estimated to have ‘language needs’ (an 
indicator of the proportion of individuals where it is likely that the first language spoken at home is 
not English).15 At the time of the study, life expectancy in HoBtPCT was shorter than the England 
average (76 years for men and 81 years for women versus 78 years and 82 years respectively 
(2006/8 figures)).17 
Aim of the study 
The aim of the Aston Medication Adherence Study (AMAS) was to examine non-adherence to 
prescribed medicines in the Heart of Birmingham teaching Primary Care Trust (HoBtPCT). 
This paper presents an overview of the results from the part of the AMAS designed to analyse 
general practice (GP) surgery prescribing data, which had the following objectives: 
• To establish the extent of non-adherence to prescribed medication in three treatment 
groups across HoBtPCT. 
• To assess variations in levels of adherence between various patient groups in HoBtPCT. 
• To design a system for the routine identification of low adherence amongst patients in 
HoBtPCT. 
Method 
Database construction 
The methodology involved the analysis of aggregated prescribing data, electronically transferred to 
Aston University via a secure electronic link, from HoBtPCT. In total, 76 General Practice (GP) 
surgeries within HoBtPCT supplied data to the interim electronic patient record (iEPR) which was 
collated at HoBtPCT. The data retrieved related to patients who had any contact with contributing 
practices within the period between 2000 and 2010 and who were coded within one of three 
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condition Read codes (dyslipidaemia, C32%; diabetes type-2, C10%; and hypothyroidism, C0%). Read 
codes are the standard classification used within UK general practice and provide a hierarchical 
system of coding for multiple patient phenomena including diagnosis, medication prescribed and a 
variety of different patient demographic factors (religion, smoking status, etc.). The data extract for 
transfer was undertaken by the Senior Database Administrator at HoBtPCT who verified the extract 
by comparison with the iEPR. During subsequent analysis, it was noted that for certain patient 
factors, complete data were not available (where applicable, this is discussed further below). 
A software programme was devised to calculate individual patient Medication Possession Ratios 
(MPRs) for all medication periods of interest. A medication possession ratio (MPR) is a measure of 
whether a patient has been issued with sufficient prescriptions to last them over a specific period of 
time. It is calculated as follows: 
Amount of medication supplied (i.e. prescription quantity)/Amount required over a 
particular period 
Although not a definitive indicator of adherence to a medication regimen (as outlined above), 
previous research has shown that a low MPR value is a valid indicator of non-adherence.7, 18 For this 
project, adherence was taken as MPR ≥0.8. 
Owing to the large time period covered by the data extraction, it was possible for patients to have 
more than one episode of a particular presentation of a medication (i.e. two or more separate 
periods of administration with a period of non-administration of that medication in between). To 
accommodate this, MPRs were calculated in “runs”. For each patient, a run commenced when an 
individual patient was first prescribed a medication for a relevant condition (or were being 
prescribed the medication at the start of the study period). The time between the first prescription 
and last prescription in the run (within the study period) was calculated and this was compared to 
the amount of medication prescribed. A run continued as long as subsequent prescriptions were 
present for the medication unless: 
• the dosage frequency of the prescribed medication was changed; 
• there was a gap of 252 days between prescriptions for the medication of interest. This was 
to ensure that if a patient stopped and restarted a medication, this medication gap was 
accounted for. This figure was chosen because some patients had prescriptions issued to 
cover up to a six-month period; 
• no other prescriptions were found; or 
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• the patient was prescribed an alternative medication for their condition. 
The run was only reported if the patient was prescribed the medication for greater than 84 days (a 
three month period, based on a pharmaceutical month of 28 days).This was to allow for an initial 
period of adjustment time when the patient started the medication. 
Analysis of the data 
For all three conditions, the computer model was able to generate MPRs for each individual patient 
run and link each MPR to individual patient demographics. Over one million individual prescription 
issues were analysed to generate the patient runs (as described above) for these three conditions as 
follows: 
• Diabetes 489,379 prescription issues; 30,949 runs from 9,445 unique patients. 
• Dyslipidaemia 278,894 prescription issues; 17,606 runs from 8,568 unique patients. 
• Hypothyroid 239,609 prescription issues; 16,942 runs from 5,674 unique patients. 
For each of the three datasets, a single output was assembled detailing each individual run alongside 
extracted patient demographics and calculated MPR values. For some patient medication runs 
within the diabetes dataset (n=238) it was not possible to calculate an MPR owing to unclear dosage 
information in the database for medication where multiple dosing frequencies are possible. For 
subsequent analysis, these patient runs were removed from the database. 
For analysis by individual demographic values (gender, age, religion, ethnicity, language and 
socioeconomic deprivation), calculated MPR values for last medication runs were analysed by 
recorded patient characteristics. Owing to variations in the level of recording of certain patient 
factors within the general practice databases, some data were missing from the analysis and so 
relevant patients were excluded from certain analysis; therefore, within the Results, individual “n” 
values are provided for each comparison as analysed populations varied. All primary analysis was 
repeated firstly limiting by gender group and secondly limiting the length of time the patient had 
been taking the medication (i.e. those patients who had been on the medication in question a 
minimum of one, two, three and four years). This enabled the identification of any gender effect on 
any statistically significant differences to be identified and to ascertain whether any identified 
factors remain if patients are taking the medication long-term. 
Owing to space constraints, results are presented at the condition-level only, with graphical 
representation of the data for the analysis of the diabetes data. Further detailed analysis by 
individual pharmacotherapeutic agent and graphical presentation of the data analysis from the 
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dyslipidaemia and hypothyroid databases can be found within the project report.19 Results from the 
demographic analysis are presented for last patient runs only. The Chi-square test of association was 
used to assess the significance of any correlations between variables (p<0.05). 
Data comparison 
The calculated MPRs were investigated further by triangulation of a selection of the results with 
available corresponding clinical values from the supplied data, and self-report medication adherence 
as measured by the 8-item Modified Morisky Scale© (MMAS-8). 
The MMAS-8 was included in a questionnaire which was distributed to a sample of 4,000 patients for 
whom their last run extended into 2011 (the time of the study). These patients were selected in 
order to reduce the likelihood that their medication had been stopped in the interregnum between 
transfer of the prescribing data and distribution of the questionnaire. Patients within the sample 
were stratified by treatment group and adherence status (dichotomised into adherent and non-
adherent groups). Questionnaire packs were assembled containing the MMAS-8 questionnaire in 
four languages (English, Punjabi, Urdu and Bengali; the four most common first languages (in order) 
according to analysis of the datasets transferred from HoBtPCT), along with a covering letter (in all 
four languages) and reply-paid envelope, and mailed via HoBtPCT to preserve patient anonymity. 
Unique database numbers were used to link questionnaire returns with database entries. 
Questionnaire translation was undertaken by a specialist translation service and translation validity 
was verified via reverse translation using a different specialist translation service. 
Ethical approval 
Approval was obtained from the Local NHS Research Ethics Committee, the Aston University 
Research Ethics Committee, NHS Research and Development, and the local NHS Caldicott Guardian 
prior to commencing data collection or analysis. 
Results 
Database analysis 
Overall patient adherence levels (examining all patient runs across the period covered by the data) 
varied by condition; over three quarters of patients were identified as being adherent to 
hypothyroid medication (78.4% (n=13,279/16,942)), with the adherence rates for diabetes 
medication and dyslipidaemia medication being similar to each other at around two thirds (67.5% 
(n=20,885/30,949) and 67.0% (n=11,796/17,606) respectively). When patient adherence levels were 
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limited to last patient runs (which were utilised for subsequent analysis to provide one run per 
relevant patient), similar patterns were observed - hypothyroid medication, 82.1% (n=4,658/5,674), 
diabetes medication, 68.6% (n=6,480/9,445) and dyslipidaemia medication, 71.0% (n=6,080/8,568) - 
indicating that there were no marked differences in overall adherence levels when last medication 
runs were compared to all patient runs. 
Further analysis was then undertaken by different demographic factors. Analysis by gender did not 
show any statistically significant differences between female and male patients for two conditions 
(diabetes, female=69.4% (n=3,165/4,558), male=69.0% (n=3,208/4,649); hypothyroid, female=82.1% 
(n=3,670/4,469), male=82.0% (n=988/1,205)). For dyslipidaemia medication, differences were seen 
between female and male patients, with female patients showing a small but statistically significant 
higher level of adherence (72.5% (n=2,972/4,101)) when compared to males (69.6% 
(n=3,108/4,467)).  
Age analysis of the data indicated that for all three conditions, the proportion of adherent patients 
increased by age group up to the 60-69 age group (see Figure 1).  
Figure 1 Here 
The majority of patients within the database did not have a religion coded (or were coded for the 
absence of a religion, i.e. ‘atheism’). In the analysis of all three databases, the large number of 
possible codes for religion had to be recoded into a smaller number of categories to enable suitable 
analysis to take place. This includes an aggregate category (termed “Less than 1%”) comprising of all 
small groupings. The analysis is therefore based on those patients where religion (or absence of 
religion) was coded in the database and differences were seen between the major religious 
groupings (see Figure 2). 
Figure 2 Here 
Ethnicity analysis of the data from the diabetes database indicated statistically significant variations 
in adherence between the major ethnic groupings used in the analysis (diabetes, range 86.8% 
(“Irish”; n=112/129) to 58.3% (“African”; n=116/199); dyslipidaemia, 86.2% (“Irish”; n=133/161) to 
54.1% (“African”; n=66/122); hypothyroid, 93.1% (“Irish”; n=162/174) to 70.9% (“Mixed”; n=39/55)). 
Statistically significant differences remained when the analysis was limited by gender and by length 
of run. 
When considering diabetes medication, adherence rates did not vary by language spoken. However, 
differences were seen when the analysis was limited to females and by length of run. No statistically 
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significant differences were noted for the analysis of language within the dyslipidaemia database 
(range 73.8% (“Bengali”; n=200/271) to 69.5% (“Unknown”; n=2,105/3,027)) or when limiting by 
gender. However, statistically significant differences were seen when analysis by length of run was 
undertaken. Finally, the analysis of the hypothyroid medication indicated statistically significant 
differences (range 84.7% (“English”; n=1,734/2,048) to 76.6% (“Urdu”; n=308/402)), which remained 
when analysis was undertaken by females and runs limited to one and two years of length. 
Analysis of the IMD2010 quintiles from the diabetes database compared to adherence levels 
indicated that in general, lower levels of adherence were observed in patients living in more 
deprived areas (see Figure 3).  
Figure 3 Here 
Correlation with clinical values 
From the dataset, it was only possible to extract sufficient data for one relevant clinical value to 
enable comparison with the data analysis and MPR values. The total cholesterol values for patients 
taking simvastatin (20 mg (n=814) and 40 mg (n=2,730)) were present in sufficient quantity and in 
both cases, correlation (R2=0.131 and 0.159 respectively) between percentage reduction and MPR of 
last medication run was observed, and analysis by Spearman’s rank correlation (Kolmogorov-
Smirnov for Percentage reduction and MPR of last medication run; 20 mg, p<0.0001; 40 mg, 
p<0.0001) indicated significance (20 mg, p<0.0001; 40 mg, p<0.0001). 
Further analysis for both 20 mg and 40 mg simvastatin patients, examining the percentage 
adherence levels within the dichotomised groups relating to a percentage cholesterol reduction of 
5% and greater and less than 5% respectively, indicated a statistically significant difference (20 mg, 
n=814, 77.1% compared to 45.5%; 40 mg, n=2,730, 76.2% compared to 37.7%; Chi, p<0.0001 in both 
cases). This difference remained when increasing to a 10% reduction (20 mg, 78.9% compared to 
48.9%; 40 mg, 78.3% compared to 39.3%), a 20% reduction (20 mg, 84.1% compared to 56.3%; 40 
mg, 82.4% compared to 49.2%) and a 30% reduction (20 mg, 87.5% compared to 66.9%; 40 mg, 
87.3% compared to 60.2%) (n=814 (adherent, n=600; non-adherent, n=214) and n=2,730 (adherent, 
n=1,940; non-adherent, n=790), Chi, p<0.0001 in all cases). 
Correlation with self-report measure of adherence 
Results from the MMAS-8 questionnaire allowed comparison of the results from the analysis of the 
data (i.e. the calculation of MPRs) with a self-report measure of adherence (overall response rates: 
diabetes, 28.1% (n=321/1,144); dyslipidaemia, 29.4% (n=338/1,151); hypothyroid, 23.9% 
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(n=332/1,138)). Analysis of the questionnaires categorised patients into one of three groups: High, 
Medium or Low adherence. To allow for those patients categorised as Medium adherence levels to 
be considered as either adherent or non-adherent, two sets of analysis were undertaken. The first 
compared patients’ dichotomised adherence status against dichotomised MMAS-8 status of either 
High or non-High (i.e. Medium or Low), and secondly against patients’ dichotomised MMAS-8 status 
of Low or non-Low (i.e. High or Medium). In all cases, statistically significant correlations were seen 
between a patient’s self-report of adherence status and the adherence status from the data analysis 
(see Table 1). 
Table 1 Here 
Discussion 
It has been established that for patients taking oral pharmacotherapy for diabetes, dyslipidaemia 
and hypothyroidism, it is possible to calculate their adherence status to prescribed medication using 
medication issue data from general practice surgeries. These results have been found to correlate 
with both a self-report measure of medication adherence and analysis of clinical values from the 
data. Further analysis has indicated a number of patient factors indicative of lower adherence levels. 
From the analysis, patients who were less than 60 years of age were likely to exhibit lower levels of 
adherence. Age is a factor reported as affecting adherence and in developed countries adherence to 
treatment by children and adolescents varies from 43% to 100% with an average of 58%.20 It has also 
been reported that adolescents are less adherent to prescribed medication regimens than younger 
children.21 The relationship between age and adherence is complicated but a number of studies have 
suggested that younger patients (those aged under 40 years22-23, under 44 years24, under 55 years25, 
under 60 years26, under 65 years27 and those with a mean age of 52 years versus 56 years28) have 
lower adherence. These published findings correlate with the findings from the present study and, 
when considered alongside the disproportionately young population within HoBtPCT, the findings 
indicate that specific targeting of any healthcare intervention to patients below the age of 60 within 
HoBtPCT would be beneficial. 
Patients coded with “Islam” as their religion were found to be less adherent to their medication than 
other patients in all three treatment groups. The literature exploring the effects of religious belief on 
adherence is sparse. A Birmingham-based study highlighted problems with medication adherence 
associated with the dietary requirements of Muslim patients.29 A total of 64% of patients and 56% of 
GPs sampled either stated that Muslims could not, or were unsure as to whether Muslims could take 
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haraam (i.e. non-halaal) medicines (such as those containing pork gelatine or alcohol) for treating 
major illnesses thus highlighting the need for further education of both Muslim patients and health 
care professionals on such matters. NICE Guidance highlights that an individuals’ religious beliefs (i.e. 
fasting behaviour) may make adherence to a regimen very difficult if not impossible.1 Therefore, in 
addition to highlighting this patient group as one which would particularly benefit from targeted 
intervention, we believe that this study provides important novel data relating to adherence levels 
across different religious groupings. 
The analysis of the data relating to ethnicity revealed statistically significant differences between 
different ethics groups. Various studies have highlighted race as a factor that affects levels of 
adherence.30-32 This issue assumes particular pertinence within HoBtPCT where seven out of ten of 
the population that HoBtPCT provides healthcare services to are black or Asian.14 Lawton et al 
explored the beliefs of diabetic patients of South Asian origin living in the UK prescribed oral 
hypoglycaemic medicines.33 These patients distrusted the healthcare systems in their countries of 
origin but admired the NHS. They consequently considered that the medicines available in the UK 
would be more efficacious than those available in their country of origin and therefore ingested 
reduced doses of their prescribed medications. Studies on the influence of ethnicity on adherence 
rates from the US suggest that black people (most commonly described in the literature as ‘African 
Americans’) are less likely to adhere to antidiabetic agents34-36 and statins25, 37 than white people. It 
would appear that the results from the present study are consistent with previously published 
studies and owing to the make-up of HoBtPCT’s population, strengthen the need to provide targeted 
adherence support to certain ethnic groups. 
Finally, a correlation was observed between adherence levels and socioeconomic deprivation, with 
those in less-deprived areas showing greater adherence levels. Lower income is a further factor that 
affects levels of adherence.31-32 As the geographical area covered by HoBtPCT includes some of 
Birmingham’s and England’s poorest, most deprived neighbourhoods this again is an issue of 
salience to this research. 
The AMAS has successfully demonstrated how a computerised tool can be employed to identify 
patients with low adherence levels to oral pharmacotherapy for the treatment of diabetes, 
dyslipidaemia and hypothyroidism and identify specific patient characteristic which may be 
indicative of lower adherence levels. Knowledge of the individual indicative factors for low 
adherence will help commissioners target specific support interventions to those patients most in 
need. However, further work is required to expand this tool into other therapeutic areas and to 
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understand further the complex interaction between the different factors to develop an even more 
in-depth understanding of the patient factors affecting adherence patterns. 
Limitations 
The project does have a number of limitations which need to be taken into consideration when 
interpreting the potential impact of the results: 
• The quality of the data analysis relied on the quality of the coding of the data present in the 
database and in the reliability of the data extraction at the PCT. Whilst the project team 
have no reason to doubt the quality of either, the team was not in a position to be able to 
check data coding quality owing to the requirement to maintain patient anonymity. 
• Parts of the data manipulation relied on the interpretation of “as directed” doses and their 
conversion into dosage and frequency values for the calculation of individual MPRs. 
• As discussed above, the specific patient demographics which have been identified as being 
indicators of lower adherence levels are likely to be linked rather than discreet indicators. 
Therefore, although each in itself is useful in assisting in the targeting of any intervention or 
support provided, further work is required to understand the complex interplay between the 
individual demographic factors. 
• The model has been designed to identify a specific group of patients who are non-adherent 
to this medication; namely those who are collecting prescriptions for their medication at a 
minimum frequency. Therefore, the figures for adherence levels within the populations 
examined have not taken into consideration low or non-adherence arising from other parts 
of the medication supply chain. 
Conclusion 
Using currently available aggregated data from GP prescribing systems, it is possible to develop a 
computerised tool to calculate individual patient MPRs for oral pharmacotherapy for the treatment 
of diabetes, dyslipidaemia and hypothyroidism. The effectiveness of the developed methodology has 
been validated by triangulation with both a self-report measure of adherence and through the 
analysis of specific clinical values. 
The developed tool has been employed to examine the adherence levels and patterns of HoBtPCT 
patients who take oral pharmacotherapy for the treatment of diabetes, dyslipidaemia and 
hypothyroidism. This analysis has identified specific patient demographics which can be used as 
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indicators of potential low adherence and has highlighted specific patient groups to target with any 
support interventions. These groups are: 
• Patients younger than 60 years of age. 
• Patients whose religion is coded as ‘Islam’. 
• Patients whose ethnicity is coded as one of the Asian groupings or coded as ‘Caribbean’, 
‘Other Black’ and ‘African’. 
• Patients whose primary language is coded as Urdu or Bengali. 
• Patients whose postcodes indicate that they live within the most socioeconomically deprived 
areas of HoBtPCT. 
Awareness of these individual patient factors will to enable the targeting of interventional support 
within HoBtPCT. 
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Figures 
Figure 1: Adherence patterns by age groupa 
 
                                                            
a Within Figure 1, for diabetes medication, adherence levels increase from around a half (49.4% (n=44/89)) for 
the 18-29 age group to around 73% (73.4% (n=1,470/2,004)) for the 60-69 age group. For dyslipidaemia 
medication, adherence levels were around half (50.9% (n=28/55)) for the 18-29 age group, increasing to 
around three-quarters (76.6% (n=1,530/1,998)) for the 60-69 age group. For hypothyroid medication, 
adherence levels were around two-thirds (65.8% (n=287/436)) for the 18-29 age group, increasing to around 
nine-tenths (89.3% (n=891/998)) for the 60-69 age group. For all three conditions, statistically significant 
differences remained when the analysis was limited by gender and by length of run. 
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Figure 2: Adherence patterns by religious groupb 
 
                                                            
b Within Figure 2, for diabetes medication, adherence ranged from 83.0% (“Less than 1%”; n=39/47) to 67.5% 
(“Islam”; n=1,664/2,465). For dyslipidaemia medication adherence ranged from 79.7% (“Protestant”; 
n=419/526) to 68.0% (“Less than 1%”; n=34/50). For hypothyroid medication, adherence ranged from 88.6% 
(“Protestant”; n=226/255) to 78.3% (“Islam”; n=791/1,010). For all three conditions, significant differences 
were seen between the “Islam” group when compared to each other individual religious grouping. Statistically 
significant differences remained for all three conditions when the analysis was limited by gender (only female 
for hyperthyroid) and by length of run (only up to greater than two years for diabetes medication). 
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Figure 3: Adherence patterns by IMD2010 quintile (Quintile 1 least deprived – Quintile 5 most deprived)c 
 
  
                                                            
c Within Figure 3, for diabetes medication, adherence ranged from 74.7% (quintile 2; n=694/929) to 67.6% 
(quintile 5; n=3,299/4,877). For dyslipidaemia medication, adherence levels ranged from 77.0% (quintile 1; 
n=268/348) to 69.1% (quintile 5; n=2,616/3,784). For hypothyroid medication, adherence ranged from 86.6% 
(quintile 1; n=253/292) to 79.4% (quintile 5; n=1,841/2,318).  For all three conditions, statistically significant 
differences remained when the analysis was limited by gender and by length of run. 
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Tables 
Table 1: Comparison of data analysis and Morisky Score categoriesd 
Questionnaire result Adherent Non-adherent Statistical result (Chi) 
Diabetes (1) 
Low/Medium (n=210) 53.8% (n=113) 46.2% (n=97) P=0.010 (n=321) High (n=111) 69.4% (n=77) 30.6% (n=34) 
Diabetes (2) 
Low (n=82) 48.8% (n=40) 51.2% (n=42) P=0.036 (n=321) Medium/High (n=239) 62.8% (n=150) 37.2% (n=89) 
Dyslipidaemia (1) 
Low/Medium (n=200) 49.5% (n=99) 50.5% (n=101) P<0.0001 (n=338) High (n=138) 75.4% (n=104) 24.6% (n=34) 
Dyslipidaemia (2) 
Low (n=103) 36.9% (n=38) 63.1% (n=65) P<0.0001 (n=338) Medium/High (n=235) 70.2% (n=165) 29.8% (n=70) 
Hypothyroid (1) 
Low/Medium (n=211) 48.3% (n=102) 51.7% (n=109) P<0.0001 (n=332) High (n=121) 81.0% (n=98) 19.0% (n=23) 
Hypothyroid (2) 
Low (n=115) 35.7% (n=41) 64.3% (n=74) P<0.0001 (n=332) Medium/High (n=217) 73.3% (n=159) 26.7% (n=58) 
 
                                                            
d High is defined as =8, Medium 6-<8, Low <6. 
